S&P 500
5.127,79 +63,59 (+1,26%) Nasdaq
16.156,33 +315,33 (+1,99%) NIKKEI 225
38.236,07 -38,03 (-0,10%) Dólar/Euro
1,0763 -0,0003 (-0,03%) Petróleo Brent
83,42 +0,46 (+0,55%) Bitcoin EUR
59.887,07 +980,84 (+1,67%)
Guardant Health, Inc. (GH)
Después del cierre:
Guardant Health, Inc.
3100 Hanover Street
Palo Alto, CA 94304
United States
855 698 8887
https://guardanthealth.com
Sector(es): Healthcare
Sector: Diagnostics & Research
Empleados a tiempo completo: 1768
Ejecutivos clave
| Nombre | Título | Paga | Ejecutado | Año de nacimiento |
|---|---|---|---|---|
| Dr. Helmy Eltoukhy Ph.D. | Co-Founder, Co-CEO & Chairman | 11,59k | N/A | 1980 |
| Dr. AmirAli Talasaz Ph.D. | Co-CEO & Director | 26,41k | N/A | 1980 |
| Mr. Michael Bell | Chief Financial Officer | 819,27k | N/A | 1969 |
| Ms. Darya Chudova | Chief Technology Officer | 715,66k | N/A | 1974 |
| Dr. Craig Eagle M.D. | Chief Medical Officer | 844,86k | N/A | 1967 |
| Mr. Christopher Freeman | Chief Commercial Officer | 826,27k | N/A | 1974 |
| Mr. Kumud Kalia | Chief Information Officer | N/A | N/A | 1966 |
| Mr. John G. Saia | Chief Legal Officer & Corporate Secretary | 627,18k | N/A | 1973 |
| Ms. Jennifer Higgins | Senior Vice President of Public Affairs | N/A | N/A | N/A |
| Ms. Terilyn Juarez Monroe | Chief People Officer | N/A | N/A | 1967 |
Descripción
Guardant Health, Inc., a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers. It offers Shield Test; Guardant Reveal Test for adjuvant treatment selection in early-stage cancer patients; Smart Liquid Biopsy Platform; and Guardant Galaxy, an AI-backed digital pathology platform that helps improve cancer biomarker detection. In addition, the company offers development services, including companion diagnostic development and regulatory approval, clinical study setup, monitoring and maintenance, testing development and support, technologies licensing, and kits fulfillment. The company has a collaboration agreement with Illumina, Inc. for the sharing of specimen samples to advance cancer research. The company was incorporated in 2011 and is headquartered in Palo Alto, California.
Gobierno corporativo
El ISS Governance QualityScore de Guardant Health, Inc., a día 1 de mayo de 2024, es 7. Las puntuaciones base son Auditoría: 1; Tablero: 7; Derechos de los accionistas: 8; Compensación: 9.
